Paloma Partners Management CO Biocryst Pharmaceuticals Inc Transaction History

Paloma Partners Management CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.59 - $3.45 $28,143 - $61,065	-17,700 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $44,250 - $66,021	17,700 New	17,700 $51,000
Q2 2019 Aug 14, 2019	SELL	$2.91 - $9.15 $40,082 - $126,032	-13,774 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $24,914 - $32,814	3,376 Added 32.47%	13,774 $112,000
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $67,690 - $99,820	10,398 New	10,398 $84,000
Q3 2018 Nov 14, 2018	SELL	$5.52 - $7.99 $167,256 - $242,097	-30,300 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$4.6 - $6.52 $139,380 - $197,556	30,300 New	30,300 $174,000
Q4 2017 Feb 14, 2018	SELL	$4.16 - $5.33 $42,964 - $55,048	-10,328 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $42,344 - $61,658	10,328	10,328 $54,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.31B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.